Who will get Pfizer’s COVID-19 vaccine?
NewsBioNTech and Pfizer have announced today that their vaccine candidate has, so far, been found to be more than 90%...
-
Russian government advised – “issue compulsory license to make generic COVID-19 drug available”
Call to action NewsFirst civil society, and now a generic drug company, have asked the Russian government to issue a compulsory license on...
-
Andrei: “The church and HIV treatment activism go hand-in-hand”
Interview“I’m never apart from this book, it’s what inspires me,” says Andrei, 44, a black leather bible firmly in his...
Read more about Andrei: “The church and HIV treatment activism go hand-in-hand”
-
TB: 9 patent oppositions against J&Js overpriced drugs
News1.2 million lives were lost to TB last year. The reduction in TB deaths annually is slow, and even these...
Read more about TB: 9 patent oppositions against J&Js overpriced drugs
-
COVID-19 & TB: Why whether you live or die is a matter of justice, not science
OpinionJohnson & Johnson, a brand built on images of happy gurgling babies and the tagline ‘no more tears’, has the...
Read more about COVID-19 & TB: Why whether you live or die is a matter of justice, not science
-
HIV2020 video: Community reclaiming the global response!
NewsThe Treatment Activist Meeting took place last week, as part of HIV2020 Online. HIV2020 is described as a key population-led, inter-disciplinary,...
Read more about HIV2020 video: Community reclaiming the global response!
-
Join the #HIV2020 Activist Meeting – this Tuesday
NewsPlease join us at the HIV2020 Treatment Activist Meeting on Tuesday 6th October! Register by Sunday 4th October. The history of the HIV...
Read more about Join the #HIV2020 Activist Meeting – this Tuesday
-
HIV: Switch to generic darunavir in Kyrgyzstan and save $53,000
Call to action NewsFirst published by the Partnership Network Association in Kyrgyzstan, read here in Russian. Analysis carried out by our campaign partner,...
Read more about HIV: Switch to generic darunavir in Kyrgyzstan and save $53,000
-
Indian Patent Office: Merck’s patent application for HIV drug, raltegravir, is “refused”
NewsA patent that Merck has been pursuing in India since 2007 has been refused by the Indian Patent Office. The...
-
Petro: Providing the protection he didn’t have
InterviewWhen Petro was a teenager selling sex, HIV treatment didn’t exist, at least not as far as he was aware,...
Read more about Petro: Providing the protection he didn’t have
